oxybutynin has been researched along with Sleep Apnea, Obstructive in 16 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
Sleep Apnea, Obstructive: A disorder characterized by recurrent apneas during sleep despite persistent respiratory efforts. It is due to upper airway obstruction. The respiratory pauses may induce HYPERCAPNIA or HYPOXIA. Cardiac arrhythmias and elevation of systemic and pulmonary arterial pressures may occur. Frequent partial arousals occur throughout sleep, resulting in relative SLEEP DEPRIVATION and daytime tiredness. Associated conditions include OBESITY; ACROMEGALY; MYXEDEMA; micrognathia; MYOTONIC DYSTROPHY; adenotonsilar dystrophy; and NEUROMUSCULAR DISEASES. (From Adams et al., Principles of Neurology, 6th ed, p395)
| Excerpt | Relevance | Reference |
|---|---|---|
| " The combination of atomoxetine and oxybutynin for the treatment of obstructive sleep apnea in children with Down syndrome." | 9.69 | The combination of atomoxetine and oxybutynin for the treatment of obstructive sleep apnea in children with Down syndrome. ( Bottrill, K; Combs, D; Edgin, J; Gerken, B; Hsu, CH; La Rue, S; Matloff, D; Parthasarathy, S; Van Vorce, H, 2023) |
| " The combination of atomoxetine and oxybutynin for the treatment of obstructive sleep apnea in children with Down syndrome." | 5.69 | The combination of atomoxetine and oxybutynin for the treatment of obstructive sleep apnea in children with Down syndrome. ( Bottrill, K; Combs, D; Edgin, J; Gerken, B; Hsu, CH; La Rue, S; Matloff, D; Parthasarathy, S; Van Vorce, H, 2023) |
| "Ato-Trazo has the potential to become a useful drug combination, however, longer trials are needed to determine the best dosage and the subgroup of patients who may benefit most from this combination." | 3.30 | Effects of atomoxetine plus a hypnotic on obstructive sleep apnea severity in patients with a moderately collapsible pharyngeal airway. ( Corser, B; Eves, E; Rucosky, G; Warren-McCormick, J, 2023) |
| "Although recent investigations combining noradrenergic and antimuscarinic drugs have shown promising short-term results to treat obstructive sleep apnea (OSA), the mid-term effect and optimal dosage remain uncertain." | 3.30 | Effect of oxybutynin and reboxetine on obstructive sleep apnea: a randomized, placebo-controlled, double-blind, crossover trial. ( Bayon, V; Berger, M; Bradley, B; Dussez, R; Haba-Rubio, J; Heiniger, G; Heinzer, R; Lecciso, G; Marchi, NA; Siclari, F; Solelhac, G; Van Den Broecke, S, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (25.00) | 24.3611 |
| 2020's | 12 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Perger, E | 2 |
| Taranto Montemurro, L | 1 |
| Rosa, D | 2 |
| Vicini, S | 2 |
| Marconi, M | 1 |
| Zanotti, L | 1 |
| Meriggi, P | 2 |
| Azarbarzin, A | 4 |
| Sands, SA | 4 |
| Wellman, A | 3 |
| Lombardi, C | 2 |
| Parati, G | 2 |
| Schweitzer, PK | 1 |
| Maynard, JP | 1 |
| Wylie, PE | 1 |
| Emsellem, HA | 1 |
| Kinouchi, T | 1 |
| Terada, J | 1 |
| Sakao, S | 1 |
| Koshikawa, K | 1 |
| Sasaki, T | 1 |
| Sugiyama, A | 1 |
| Sato, S | 1 |
| Sakuma, N | 1 |
| Abe, M | 1 |
| Shikano, K | 1 |
| Hayama, N | 1 |
| Shiko, Y | 1 |
| Ozawa, Y | 1 |
| Ikeda, S | 1 |
| Suzuki, T | 1 |
| Tatsumi, K | 1 |
| Edwards, BA | 1 |
| Joosten, SA | 1 |
| Corser, B | 1 |
| Eves, E | 1 |
| Warren-McCormick, J | 1 |
| Rucosky, G | 1 |
| Castiglioni, P | 1 |
| Faini, A | 1 |
| Soranna, D | 1 |
| Zambon, A | 1 |
| Pini, L | 1 |
| Baratto, C | 1 |
| Caravita, S | 1 |
| Berger, M | 1 |
| Solelhac, G | 1 |
| Marchi, NA | 1 |
| Dussez, R | 1 |
| Bradley, B | 1 |
| Lecciso, G | 1 |
| Heiniger, G | 1 |
| Bayon, V | 1 |
| Van Den Broecke, S | 1 |
| Haba-Rubio, J | 1 |
| Siclari, F | 1 |
| Heinzer, R | 1 |
| Combs, D | 1 |
| Edgin, J | 1 |
| Hsu, CH | 1 |
| Bottrill, K | 1 |
| Van Vorce, H | 1 |
| Gerken, B | 1 |
| Matloff, D | 1 |
| La Rue, S | 1 |
| Parthasarathy, S | 1 |
| Taranto-Montemurro, L | 3 |
| Messineo, L | 2 |
| Vena, D | 1 |
| Hess, LB | 1 |
| Calianese, NA | 1 |
| White, DP | 1 |
| Lavigne, G | 1 |
| Herrero Babiloni, A | 1 |
| Fabbro, CD | 1 |
| Mayer, P | 1 |
| Chen, TY | 1 |
| Chung, CH | 1 |
| Chang, HA | 1 |
| Kao, YC | 1 |
| Chang, SY | 1 |
| Kuo, TBJ | 1 |
| Yang, CCH | 1 |
| Chien, WC | 1 |
| Tzeng, NS | 1 |
| Carter, SG | 1 |
| Chiang, A | 1 |
| Vakulin, A | 1 |
| Adams, RJ | 1 |
| Carberry, JC | 1 |
| Eckert, DJ | 1 |
| Wadman, M | 1 |
| Fleury Curado, T | 1 |
| Berger, S | 1 |
| Polotsky, VY | 1 |
| Patel, SR | 1 |
| Althouse, AD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Reboxetine for Obstructive Sleep Apnoea After Upper Airway Surgery: a Randomised, Double-blind, Placebo-controlled Study[NCT05978505] | Phase 2 | 20 participants (Anticipated) | Interventional | 2023-08-15 | Not yet recruiting | ||
| Crossover, Double-blind, Phase 2 Study of AD128 Versus Placebo in Obstructive Sleep Apnea[NCT04449133] | Phase 2 | 20 participants (Actual) | Interventional | 2020-07-03 | Completed | ||
| Phase 2, Randomized, 3-Period, Placebo-Controlled Crossover Study to Evaluate the Efficacy and Safety in Obstructive Sleep Apnea of AD036 Versus Placebo or Atomoxetine[NCT04445688] | Phase 2 | 62 participants (Actual) | Interventional | 2020-07-15 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Apnea-Hypopnea Index(Disease severity is often defined based on the number of apneas and hypopneas per hour during sleep), AD036 vs. placebo (NCT04445688)
Timeframe: 1 day
| Intervention | events/hour (Least Squares Mean) |
|---|---|
| AD036 | 11.5 |
| Atomoxetine | 11.5 |
| Placebo | 18.8 |
Hypoxic burden (a way to measure oxygen desaturation) determined by measuring the respiratory event-associated area under the desaturation curve from pre-event baseline, AD036 vs. placebo. Hypoxic Burden was measured during polysomnography (type of sleep study), while the patient was asleep (NCT04445688)
Timeframe: 1 day
| Intervention | %min/hour (Least Squares Mean) |
|---|---|
| AD036 | 24.3 |
| Atomoxetine | 26.8 |
| Placebo | 46.1 |
Oxygen Desaturation Index, measured by pulse-oximetry, AD036 vs. placebo (NCT04445688)
Timeframe: 1 day
| Intervention | events/hour (Least Squares Mean) |
|---|---|
| AD036 | 12.8 |
| Atomoxetine | 13.3 |
| Placebo | 20.1 |
9 trials available for oxybutynin and Sleep Apnea, Obstructive
| Article | Year |
|---|---|
Reboxetine Plus Oxybutynin for OSA Treatment: A 1-Week, Randomized, Placebo-Controlled, Double-Blind Crossover Trial.
Topics: Adrenergic Uptake Inhibitors; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Fe | 2022 |
Reboxetine Plus Oxybutynin for OSA Treatment: A 1-Week, Randomized, Placebo-Controlled, Double-Blind Crossover Trial.
Topics: Adrenergic Uptake Inhibitors; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Fe | 2022 |
Reboxetine Plus Oxybutynin for OSA Treatment: A 1-Week, Randomized, Placebo-Controlled, Double-Blind Crossover Trial.
Topics: Adrenergic Uptake Inhibitors; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Fe | 2022 |
Reboxetine Plus Oxybutynin for OSA Treatment: A 1-Week, Randomized, Placebo-Controlled, Double-Blind Crossover Trial.
Topics: Adrenergic Uptake Inhibitors; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Fe | 2022 |
Efficacy of atomoxetine plus oxybutynin in the treatment of obstructive sleep apnea with moderate pharyngeal collapsibility.
Topics: Atomoxetine Hydrochloride; Cross-Over Studies; Humans; Sleep; Sleep Apnea, Obstructive | 2023 |
Effects of the combination of atomoxetine and oxybutynin in Japanese patients with obstructive sleep apnoea: A randomized controlled crossover trial.
Topics: Atomoxetine Hydrochloride; Cross-Over Studies; East Asian People; Humans; Oxygen; Prospective Studie | 2023 |
Effects of atomoxetine plus a hypnotic on obstructive sleep apnea severity in patients with a moderately collapsible pharyngeal airway.
Topics: Atomoxetine Hydrochloride; Humans; Hypnotics and Sedatives; Pharynx; Sleep Apnea, Obstructive | 2023 |
Impact of reboxetine plus oxybutynin treatment for obstructive sleep apnea on cardiovascular autonomic modulation.
Topics: Autonomic Nervous System; Blood Pressure Monitoring, Ambulatory; Heart Rate; Humans; Middle Aged; Re | 2023 |
Effect of oxybutynin and reboxetine on obstructive sleep apnea: a randomized, placebo-controlled, double-blind, crossover trial.
Topics: Cross-Over Studies; Double-Blind Method; Humans; Male; Oxygen; Reboxetine; Sleep Apnea, Obstructive | 2023 |
The combination of atomoxetine and oxybutynin for the treatment of obstructive sleep apnea in children with Down syndrome.
Topics: Atomoxetine Hydrochloride; Child; Down Syndrome; Humans; Quality of Life; Sleep Apnea, Obstructive; | 2023 |
Effects of the Combination of Atomoxetine and Oxybutynin on OSA Endotypic Traits.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Continuous Positive Airway Pressure; Cross- | 2020 |
Addition of zolpidem to combination therapy with atomoxetine-oxybutynin increases sleep efficiency and the respiratory arousal threshold in obstructive sleep apnoea: A randomized trial.
Topics: Arousal; Atomoxetine Hydrochloride; Humans; Mandelic Acids; Sleep; Sleep Apnea, Obstructive; Zolpide | 2021 |
7 other studies available for oxybutynin and Sleep Apnea, Obstructive
| Article | Year |
|---|---|
Variability in the response to atomoxetine and oxybutynin for OSA: Highlighting the need for personalized medicine.
Topics: Atomoxetine Hydrochloride; Humans; Precision Medicine; Sleep; Sleep Apnea, Obstructive | 2023 |
Could Atomoxetine-Oxybutynin, a Combination of Medications Being Explored for OSA Management, Have Any Effect on Sleep Bruxism or Jaw Muscle Tone?
Topics: Atomoxetine Hydrochloride; Humans; Mandelic Acids; Muscle Tonus; Sleep Apnea, Obstructive; Sleep Bru | 2021 |
Long-term atomoxetine-oxybutynin combination use may be beneficial for the prevention of obstructive sleep apnea.
Topics: Adolescent; Adult; Aged; Atomoxetine Hydrochloride; Child; Child, Preschool; Databases, Factual; Dru | 2021 |
Drug pair shows promise for treating sleep apnea.
Topics: Airway Obstruction; Atomoxetine Hydrochloride; Humans; Mandelic Acids; Sleep Apnea, Obstructive | 2018 |
Pharmacotherapy of Obstructive Sleep Apnea: Is Salvation Just Around a Corner?
Topics: Atomoxetine Hydrochloride; Cross-Over Studies; Double-Blind Method; Humans; Mandelic Acids; Sleep Ap | 2019 |
Reply to Patel and Althouse: Robust Methods Are Needed to Evaluate the Pharmacologic Treatment of Obstructive Sleep Apnea.
Topics: Atomoxetine Hydrochloride; Cross-Over Studies; Double-Blind Method; Humans; Mandelic Acids; Sleep Ap | 2019 |
Robust Methods Are Needed to Evaluate the Pharmacologic Treatment of Obstructive Sleep Apnea.
Topics: Atomoxetine Hydrochloride; Cross-Over Studies; Double-Blind Method; Humans; Mandelic Acids; Sleep Ap | 2019 |